Pfizer (PFE) Earns Coverage Optimism Score of 0.13
Press coverage about Pfizer (NYSE:PFE) has trended somewhat positive on Monday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pfizer earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.9219028528061 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Pfizer Raises Dividend 6%, Sets New $10 Billion Buyback Program (morningstar.com)
- UPDATE 1-Pfizer announces new $10 bln share buyback, hikes dividend (PFE, BA, BAC) (markets.businessinsider.com)
- Tax Reform Stocking Stuffer: Pfizer Dividend Hike & Much Larger Stock Buyback (247wallst.com)
- Pfizer Declares First-Quarter 2018 Dividend (finance.yahoo.com)
- Pfizer sets new $10 billion stock buyback program, bumps up dividend by 6.3% (finance.yahoo.com)
Shares of Pfizer (PFE) traded up $0.74 on Monday, reaching $37.20. The company’s stock had a trading volume of 37,779,900 shares, compared to its average volume of 19,962,043. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer has a one year low of $30.90 and a one year high of $37.22. The firm has a market capitalization of $221,560.00, a price-to-earnings ratio of 14.88, a P/E/G ratio of 2.62 and a beta of 1.01.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.66%. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.
A number of research analysts have recently weighed in on PFE shares. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a report on Tuesday, September 19th. Deutsche Bank set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Barclays set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. BMO Capital Markets set a $37.00 target price on Pfizer and gave the stock a “buy” rating in a report on Tuesday, October 10th. Finally, ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $38.77.
In other Pfizer news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.